Indian Pediatrics

, Volume 56, Issue 9, pp 767–771 | Cite as

Mass Administration of Azithromycin to Prevent Pre-school Childhood Mortality: Boon or Bane?

  • Joseph L. MathewEmail author
  • Rashna DasEmail author
Journal Club


A group of American researchers funded by the Bill and Melinda Gates Foundation examined the effect of mass administration of azithromycin, on mortality in pre-school children. This was done through a community-based randomized controlled trial (RCT) designated MORDOR-I, conducted in Malawi, Niger, and Tanzania [1]. MORDOR is an acronym for the French title of the study. Community clusters of children (1 month to 5-year-old) were randomized to receive either azithromycin (single dose 20 mg/kg, administered twice a year for 2 years) or identical placebo (in the same dosage schedule). The overall mortality rate (expressed as deaths per 1000 person years) was 13.5% lower in the treatment arm, with 95% confidence interval 6.7% to 19.8% (hence statistically significant). However, detailed analysis showed that only communities in Niger had statistically significant mortality reduction to the extent of 18% (95% CI 10%, 25.5%), whereas those in Malawi and Tanzania did not. Thus, the overall mortality reduction was largely due to the reduction in Niger. This significant intercountry difference was partly attributed to higher baseline mortality in Niger, and stronger effect of mass azithromycin administration in such settings [2]. The investigators then evaluated the administration of two doses of azithromycin (6 months apart) in children from both groups of communities in Niger only. Thus, communities in the original Azithromycin group (in MORDOR-I) received a total of 6 doses, whereas those in the original placebo group received 2 doses. This part of the study has been designated MORDOR-II [3], and is examined in detail here. Communities in Malawi and Tanzania that did not show mortality decline were not evaluated any further.

The primary outcome in MORDOR-II [3] was the same as in MORDOR-I viz. all-cause mortality at the community level. Secondary outcomes included intra-group comparison of mortality. Although safety data were mentioned in the manuscript [3], the data were not presented. The results showed a comparable mortality rate (expressed as deaths per 1000 person-years) among children who received 6 doses of azithromycin over three years versus those who received 2 doses over 1 year. In contrast, the mortality after administration of 2 doses and 4 doses of azithromycin (versus similar doses of placebo) was 16.0% and 20.3% lower respectively, in the azithromycin group. Intra-group comparison showed that mortality in the original placebo group was 26.3 at the end of year 1 of MORDOR-I, 28.0 at the end of year 2 of MORDOR-I, and 24.0 at the end of MORDOR-II. This translated to an overall (statistically significant) 13.5% reduction in mortality between pre-MORDOR-I and post-MORDOR-II. In contrast, the intra-group comparison in the azithromycin group showed a 3.6% higher mortality after MORDOR-II, compared to before MORDOR-I (although the difference was not statistically significant). The authors reiterated their original conclusion that mass administration of azithromycin reduced mortality among pre-school children in Niger [1,3], and additional administration of two doses did not appear to wane this effect. However, there was no additional benefit on mortality with the third year of mass azithromycin administration.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


Acknowledgement: Dr Melody Baruah, Consultant Microbiologist, Health City Hospital, Guwahati, India for the local azithromycin sensitivity results.

Funding: None.


  1. 1.
    Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, et al. Azithromycin to reduce childhood mortality in Sub-Saharan Africa. N Engl J Med. 2018;37: 1583–92.CrossRefGoogle Scholar
  2. 2.
    Oron AP, Burstein R, Mercer LD, Arzika AM, Kalua K, Mrango Z, et al. Effect modification by baseline mortality in the MORDOR Azithromycin trial. Am J Trop Med Hyg. 2019 Feb 7. (Epub ahead of print).Google Scholar
  3. 3.
    Keenan JD, Arzika AM, Maliki R, Boubacar N, Elh Adamou S, Moussa Ali M, et al. Longer-term assessment of Azithromycin for reducing childhood mortality in Africa. N Engl J Med. 2019;380:2207–14.CrossRefGoogle Scholar
  4. 4.
    Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ. 2014;348:1908.CrossRefGoogle Scholar
  5. 5.
    Svanstrom H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013;368:1704–12.CrossRefGoogle Scholar
  6. 6.
    Gorelik E, Masarwa R, Perlman A, Rotshild V, Muszkat M, Matok I. Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides. Antimicrob Agents Chemother. 2018; 62: e00438–18.CrossRefGoogle Scholar
  7. 7.
    Xu P, Zeng L, Xiong T, Choonara I, Qazi S, Zhang L. Safety of azithromycin in pediatrics: A systematic review protocol. BMJ Pediatr Open. 2019;3: e000469.CrossRefGoogle Scholar
  8. 8.
    Oldenburg CE, Arzika AM, Maliki R, Kane MS, Lebas E, Ray KJ, et al. Safety of azithromycin in infants under six months of age in Niger: A community randomized trial. PLoS Negl Trop Dis. 2018;12: e0006950.CrossRefGoogle Scholar
  9. 9.
    Hansen MP, Scott AM, McCullough A, Thorning S, Aronson JK, Beller EM, et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2019;1: CD011825.PubMedGoogle Scholar
  10. 10.
    Porco TC, Hart J, Arzika AM, Weaver J, Kalua K, Mrango Z, et al. Mass oral azithromycin for childhood mortality: timing of death after distribution in the MORDOR trial. Clin Infect Dis. 2019;68:2114–16.CrossRefGoogle Scholar
  11. 11.
    O’Brien KS, Emerson P, Hooper PJ, Reingold AL, Dennis EG, Keenan JD, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis. 2019;19:e14–e5.CrossRefGoogle Scholar
  12. 12.
    See CW, O’Brien KS, Keenan JD, Stoller NE, Gaynor BD, Porco TC, et al. The effect of mass Azithromycin distribution on childhood mortality: Beliefs and estimates of efficacy. Am J Trop Med Hyg. 2015; 93:1106–9CrossRefGoogle Scholar
  13. 13.
    Arzika AM, Maliki R, Boubacar N, Kane S, Cotter SY, Lebas E, et al. Biannual mass Azithromycin distributions and malaria parasitemia in pre-school children in Niger: A cluster-randomized, placebo-controlled trial. PLoS Med. 2019;16: e1002835.CrossRefGoogle Scholar
  14. 14.
    Doan T, Hinterwirth A, Worden L, Arzika AM, Maliki R, Abdou A, Kane S, et al. Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution. Nat Med. 2019. doi: CrossRefGoogle Scholar
  15. 15.
    Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms. Front Immunol. 2018;9:302.CrossRefGoogle Scholar
  16. 16.
    Tam CC, Offeddu V, Lim JM, Voo TC. One drug to treat them all: Ethical implications of the MORDOR trial of mass antibiotic administration to reduce child mortality. J Glob Health. 2019;1:010305.CrossRefGoogle Scholar
  17. 17.
    Cutler T, Jannat-Khah D, Evans A. Azithromycin and childhood mortality in Africa. N Engl J Med. 2018;379:1382–84.CrossRefGoogle Scholar
  18. 18.
    Sharma P, Kumari B, Dahiya S, Kulsum U, Kumar S, Manral N, et al. Azithromycin resistance mechanisms in typhoidal salmonellae in India: A 25 years analysis. Indian J Med Res. 2019;149:404–11.CrossRefGoogle Scholar
  19. 19.
    Makkar A, Gupta S, Khan ID, Gupta RM, Rajmohan KS, Chopra H, et al. Epidemiological profile and antimicrobial resistance pattern of enteric fever in a tertiary care hospital of North India — a seven-year ambispective study. Acta Medica. 2018;61:125–30.PubMedGoogle Scholar
  20. 20.
    Sharma P, Dahiya S, Manral N, Kumari B, Kumar S, Pandey S, et al. Changing trends of culture-positive typhoid fever and antimicrobial susceptibility in a tertiary care North Indian hospital over the last decade. Indian J Med Microbiol 2018; 36:70–76.CrossRefGoogle Scholar


  1. 1.
    UNICEF. Monitoring the situation of children and women. India (IND) — Demographics, Health & Infant Mortality — UNICEF DATA. Available from: Accessed August 22, 2019.
  2. 2.
    Liu Li, Chu Y, Oza S, Hogan D, Perin J, Bassani DG, et al. National, regional, and state-level all-cause and casue-specific under 5 mortality in India 2000–15: a systematic analysis with implications for the Sustainable Developmental Goals. Lancet Glob Health. 2019;7: e721–34.CrossRefGoogle Scholar
  3. 3.
    Mejia-Guevara I, Zuo W, Bendavid E, Li N, Tuljapurkar S. Age distribution, trends, and forecasts of under-5 mortality in 31 sub-Saharan African countries: A modeling study. PLoS Med. 2019;16:e1002757.CrossRefGoogle Scholar
  4. 4.
    Patel SR, Arti S, Pratap CB, Nath G. Drug resistance pattern in the recent isolates of S. typhi with special reference to cephalosporin and azithromycin in the Gangetic plain. J Clin Diagn Res. 2017;11:DM01–03.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Rasheed MK, Hasan SS, Babar Z, Ahmed SI. Extensively drug-resistant typhoid fever in Pakistan. Lancet Infect Dis. 2019;19:242–3.CrossRefGoogle Scholar
  6. 6.
    Ghosh R, Uppal B, Aggarwal P, Chakrabarti A, Jha AK. Increasing antimicrobial resistance of Campylobacter jejuni isolated from pediatric diarrhoea cases in a tertiary care hospital of New Delhi, India. J Clin Diagn Res. 2013;7: 247–9.PubMedPubMedCentralGoogle Scholar

Copyright information

© Indian Academy of Pediatrics 2019

Authors and Affiliations

  1. 1.Department of PediatricsPGIMERChandigarhIndia
  2. 2.Department of PediatricsHealth City HospitalGuwahatiIndia

Personalised recommendations